Spike Protein News and Research

RSS

Study: COVID-19 vaccines may remain effective against new influenza viruses

Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses.

26 Mar 2021

Antibody used for COVID-19 therapy does not inhibit SARS-Cov-2 variants

Cell culture studies show that mutated viruses are less susceptible to inhibition by antibodies from recovered or vaccinated individuals.

26 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

Study finds rapid spread of B.1.1.220 variant with E484K mutation in New York

New research led by Patrick McGann from Walter Reed Army Institute of Research found the first cases of the B.1.1.220 variant with an E484K mutation on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Their results suggest the variant recently emerged as B.1.1.220 was not found in New York before December 2020. Still, it quickly made up 25% of coronavirus strains in late January and early February.

24 Mar 2021

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

A recent study from France showed that the UK variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – also known as B.1.1.7 variant – can replicate much more efficiently in a reconstituted human bronchial epithelium, which may explain why it spreads so rapidly in the human population. The study is currently freely available on the bioRxiv preprint server.

24 Mar 2021

New compound may provide a basis for drug development against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

24 Mar 2021

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.

24 Mar 2021

Reduced mRNA COVID-19 vaccine response in nursing home residents

A recent study has examined the response of nursing home residents who were naïve to SARS-CoV-2 infection following vaccination by the mRNA BNT162b2 model from Pfizer-BioNTech.

24 Mar 2021

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Researchers at the Division of Infection and Immunity, University College London, UK, have provided key insights into the characteristics of the B.1.1.7 (or UK) variant of SARS-CoV-2.

24 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

A new study describes the use of a combination of virtual and experimental screening protocols to identify potential inhibitors of the virus, which could lead to rapid drug development.

24 Mar 2021

Detecting SARS-CoV-2 specific IgG antibodies with the Kantaro Covid-SeroKlir Kit

In this interview, Gary Dowthwaite, the Special Projects co-ordinator at EKF Diagnostics, talks to News-Medical about the Kantaro COVID-SeroKlir Kit.

From EKF Diagnostics 24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

Study reveals arsenal used by protozoans to make leishmaniasis more severe

Researchers have succeeded in revealing the arsenal used by protozoans of the genus Leishmania in human cells to make leishmaniasis more severe, especially in cases of the mucocutaneous variety of the disease, which can cause deformations in patients.

24 Mar 2021

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Now, new research published on the bioRxiv preprint server focuses on the effect of some typical ingredients present in commercially available mouthwashes and toothpaste on the mechanisms of SARS-CoV-2 entry into host cells.

24 Mar 2021

Glycans play a key role in COVID-19 infection, shows study

A research group at the RIKEN Center for Computational Science (R-CCS) has found that glycans—sugar molecules—play an important role in the structural changes that take place when the virus which causes COVID-19 invades human cells.

24 Mar 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

Spike Protein News and Research

Study: COVID-19 vaccines may remain effective against new influenza viruses

Antibody used for COVID-19 therapy does not inhibit SARS-Cov-2 variants

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Study finds rapid spread of B.1.1.220 variant with E484K mutation in New York

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

New compound may provide a basis for drug development against COVID-19

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

Reduced mRNA COVID-19 vaccine response in nursing home residents

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

Detecting SARS-CoV-2 specific IgG antibodies with the Kantaro Covid-SeroKlir Kit

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

Study reveals arsenal used by protozoans to make leishmaniasis more severe

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Glycans play a key role in COVID-19 infection, shows study

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

Pioneering Live Cell Imaging - Yokogawa's Impact and Innovations

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Latest News